Leidos Biomedical Research, Inc. (LBRI), a wholly owned subsidiary of Leidos, operates the Frederick National Laboratory for Cancer Research (FNLCR). FNLCR is a Federally Funded Research and Development Center (FFRDC) sponsored by the National Cancer Institute (NCI). It is the only FFRDC dedicated to biomedical research. Through its status as an FFRDC, FNLCR provides NCI and others with a unique national resource to accelerate the development and delivery of effective preventive, diagnostic, and therapeutic products for cancer and AIDS.
The breadth of FNLCR’s activities spans the research and development spectrum, including investigator-initiated, hypothesis-driven research into cancer and AIDS; advanced technology programs focused on genetics and genomics, proteins and proteomics, imaging, nanotechnology, bioinformatics, and laboratory animal sciences; clinical operations in support of NCI and National Institute of Allergy and Infectious Diseases (NIAID)-sponsored clinical trials, as well as NCI drug discovery and development efforts; and management and operations of biopharmaceutical development and manufacturing programs under current Good Manufacturing Practice conditions for NCI and NIAID. Administrative, procurement, financial, safety, and facilities support is provided to these R&D activities through state-of-the-art business processes. LBRI has approximately 1,900 employees and manages an annual operating budget of approximately $450M.
For more information about Leidos Biomedical Research Inc., please visit our webpage at www.leidosbiomed.com.
The Cancer Research Technology Program (CRTP) develops and implements emerging technology, cancer biology expertise and research capabilities to accomplish NCI research objectives. The CRTP is an outward-facing, multi-disciplinary hub purposed to enable the external cancer research community. The CRTP hosts the Nanotechnology Characterization Laboratory (NCL) which performs and standardizes preclinical efficacy and toxicity testing of nanoparticles intended for cancer therapeutics and diagnostics.
The Nanotechnology Characterization Lab (NCL) serves as a national resource and knowledge base for all cancer researchers to facilitate the regulatory review of nanotechnologies intended for cancer therapies and diagnostics. By providing the critical infrastructure and characterization services to nanomaterial providers, the NCL accelerates the transition of basic nanoscale particles and devices into clinical applications.
The Scientist I will:
1) Assist in the physicochemical characterization and development of new analytical methods for evaluating nanomedicines
2) Perform daily operation of AF4/SEC-MALS, RP-HPLC, DLS, and PALS instruments
3) Serve as a technical authority and mentor in the absence of the lead laboratory scientist
4) Be responsible for formal reporting of data including presentations and/or publications
5) Stay abreast of current research techniques and remain knowledgeable in pertinent areas through reading literature and by attending scientific presentations.
• Possession of a Doctoral degree in Organic Chemistry, Analytical Chemistry, Medicinal Chemistry, Chemical Engineering or related discipline from an accredited college or university according to the Council for Higher Education Accreditation (CHEA) or eight (8) years related experience in lieu of degree
• Foreign degrees must be evaluated for U.S. equivalency.
• No work experience beyond the doctorate education is required for appointment at this level; however, some candidates may have had one or more years of postdoctoral research and training.
• Experience with physicochemical characterization of nanoparticles using methods such as AF4/SEC, RP-HPLC, and MALS/DLS
• Formulation experience of nanotechnology-based drug delivery platforms
• Ability to perform complex assignments independently, as well as work effectively as part of an interdisciplinary team
• Demonstrated analytical problem solving skills
• Experience writing scientific narratives to accompany data
Leidos is a global science and technology solutions leader working to solve the world's toughest challenges in the defense, intelligence, homeland security, civil, and health markets. The company’s 33,000 employees support vital missions for government and commercial customers. Headquartered in Reston, Virginia, Leidos reported pro forma annual revenues of approximately $10 billion for the fiscal year ended January 1, 2016 after giving effect to the recently completed combination of Leidos with Lockheed Martin's Information Systems & Global Solutions business (IS&GS). For more information, visit www.Leidos.com. The company’s diverse employees support vital missions for government and commercial customers. Qualified women, minorities, individuals with disabilities and protected veterans are encouraged to apply.